BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAE1. A total of 43 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $6,271,000 | +17.8% | 6,000,000 | +20.0% | 4.60% | +10.8% |
| Q2 2018 | $5,323,000 | +3.7% | 5,000,000 | 0.0% | 4.15% | +15.9% |
| Q1 2018 | $5,134,000 | +7.1% | 5,000,000 | +13.6% | 3.58% | +6.2% |
| Q4 2017 | $4,792,000 | +374.9% | 4,400,000 | +388.9% | 3.37% | +431.2% |
| Q3 2017 | $1,009,000 | +1.3% | 900,000 | 0.0% | 0.63% | +55.8% |
| Q2 2017 | $996,000 | -2.8% | 900,000 | 0.0% | 0.41% | +9.4% |
| Q1 2017 | $1,025,000 | -52.1% | 900,000 | -52.6% | 0.37% | -52.4% |
| Q4 2016 | $2,140,000 | -9.4% | 1,900,000 | -3.3% | 0.78% | +5.5% |
| Q3 2016 | $2,362,000 | -39.3% | 1,965,000 | -43.3% | 0.74% | -32.0% |
| Q2 2016 | $3,889,000 | -2.8% | 3,465,000 | 0.0% | 1.09% | +10.0% |
| Q1 2016 | $4,002,000 | +35.4% | 3,465,000 | +38.6% | 0.99% | -33.2% |
| Q4 2014 | $2,956,000 | -44.8% | 2,500,000 | -50.0% | 1.48% | -49.0% |
| Q3 2014 | $5,356,000 | +2.8% | 5,000,000 | 0.0% | 2.91% | -0.8% |
| Q2 2014 | $5,210,000 | – | 5,000,000 | – | 2.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MACKAY SHIELDS LLC | 25,176,000 | $27,679,000 | 1.40% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 37,155,000 | $40,718,000 | 0.64% |
| OAKTREE CAPITAL MANAGEMENT LP | 24,250,000 | $26,747,000 | 0.50% |
| Jabre Capital Partners S.A. | 3,500,000 | $3,838,000 | 0.37% |
| Calamos Advisors LLC | 40,441,000 | $44,067,000 | 0.28% |
| Calamos Wealth Management LLC | 669,000 | $729,000 | 0.22% |
| Baker Brothers Advisors | 12,500,000 | $13,699,000 | 0.17% |
| PALISADE CAPITAL MANAGEMENT, LP | 5,024,000 | $5,508,000 | 0.14% |
| SSI INVESTMENT MANAGEMENT LLC | 1,127,000 | $1,236,000 | 0.13% |
| Compagnie Lombard Odier SCmA | 1,300,000 | $1,423,000 | 0.06% |